Evidence map›Paper›PMID 35971069›Full record

ArticleBMC medical research methodology2022

On model-based time trend adjustments in platform trials with non-concurrent controls.

Marta Bofill Roig, Pavla Krotka, Carl-Fredrik Burman, Ekkehard Glimm, Stefan M Gold, Katharina Hees, Peter Jacko, Franz Koenig, Dominic Magirr, Peter Mesenbrink and 2 more

Abstract read
In one paragraph

Article in BMC medical research methodology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Marta Bofill RoigCenter for Medical Statistics, Informatics and Intelligent Systems, Medical University of Vienna, Vienna, Austria.
Pavla KrotkaCenter for Medical Statistics, Informatics and Intelligent Systems, Medical University of Vienna, Vienna, Austria.
Carl-Fredrik BurmanStatistical Innovation, Data Science & Artificial Intelligence, AstraZeneca, Gothenburg, Sweden.
Ekkehard GlimmAdvanced Methodology and Data Science, Novartis Pharma AG, Basel, Switzerland.
Stefan M GoldKlinik für Psychiatrie und Psychotherapie, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Katharina HeesSection of Biostatistics, Paul-Ehrlich-Institut, Langen, Germany.
Peter JackoBerry Consultants, Abingdon, UK.
Franz KoenigCenter for Medical Statistics, Informatics and Intelligent Systems, Medical University of Vienna, Vienna, Austria.
Dominic MagirrAdvanced Methodology and Data Science, Novartis Pharma AG, Basel, Switzerland.
Peter MesenbrinkAnalytics Global Drug Development, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Kert VieleBerry Consultants, Austin, TX, USA.
Martin PoschCenter for Medical Statistics, Informatics and Intelligent Systems, Medical University of Vienna, Vienna, Austria. martin.posch@meduniwien.ac.at.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPlatform trials can evaluate the efficacy of several experimental treatments compared to a control. The number of experimental treatments is not fixed, as arms may be added or removed as the trial progresses. Platform trials are more efficient than independent parallel group trials because of using shared control groups. However, for a treatment entering the trial at a later time point, the control group is divided into concurrent controls, consisting of patients randomised to control when that treatment arm is in the platform, and non-concurrent controls, patients randomised before. Using non-concurrent controls in addition to concurrent controls can improve the trial's efficiency by increasing power and reducing the required sample size, but can introduce bias due to time trends.

methodsWe focus on a platform trial with two treatment arms and a common control arm. Assuming that the second treatment arm is added at a later time, we assess the robustness of recently proposed model-based approaches to adjust for time trends when utilizing non-concurrent controls. In particular, we consider approaches where time trends are modeled either as linear in time or as a step function, with steps at time points where treatments enter or leave the platform trial. For trials with continuous or binary outcomes, we investigate the type 1 error rate and power of testing the efficacy of the newly added arm, as well as the bias and root mean squared error of treatment effect estimates under a range of scenarios. In addition to scenarios where time trends are equal across arms, we investigate settings with different time trends or time trends that are not additive in the scale of the model.

resultsA step function model, fitted on data from all treatment arms, gives increased power while controlling the type 1 error, as long as the time trends are equal for the different arms and additive on the model scale. This holds even if the shape of the time trend deviates from a step function when patients are allocated to arms by block randomisation. However, if time trends differ between arms or are not additive to treatment effects in the scale of the model, the type 1 error rate may be inflated.

conclusionsThe efficiency gained by using step function models to incorporate non-concurrent controls can outweigh potential risks of biases, especially in settings with small sample sizes. Such biases may arise if the model assumptions of equality and additivity of time trends are not satisfied. However, the specifics of the trial, scientific plausibility of different time trends, and robustness of results should be carefully considered.

Indexed as

Sample SizeAdaptive Clinical Trials as TopicBiasHumansRandomized Controlled Trials as TopicAdding armsNon-concurrent controlsPlatform trials

Identifiers

PMID35971069
PMCPMC9380382

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.